Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE  >  Celltrion, Inc.    068270   KR7068270008

CELLTRION, INC.

(068270)
  Report  
 SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (KRW)
Sales 2019 1 012 B
EBIT 2019 461 B
Net income 2019 319 B
Finance 2019 221 B
Yield 2019 0,01%
Sales 2020 1 313 B
EBIT 2020 537 B
Net income 2020 506 B
Finance 2020 505 B
Yield 2020 0,02%
P/E ratio 2019 74,1x
P/E ratio 2020 47,2x
EV / Sales2019 23 276x
EV / Sales2020 17 947x
Capitalization 23 562 B
More Financials
Company
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as... 
More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
06/27VEEVA : Celltrion Adopts Veeva Vault eTMF for Greater Visibility into Trial Acti..
AQ
04/17CELLTRION : unveils P2 trial results for influenza antibody therapy
AQ
04/16CELLTRION : Diverging from US, Canada Approves Biosimilar Rituximab in Both Onco..
AQ
04/10CELLTRION : and iProgen Biotech announce partnership for development of novel AD..
AQ
04/07CELLTRION : Partners with the Canadian Biotech Company, iProgen Biotech to Devel..
BU
04/05CELLTRION : Completes Enrollment of Phase 3 Trial of CT-P17, Gives Update on Sub..
AQ
03/26CELLTRION : licenses out hypertrophic cardiomyopathy treatment to Japan
AQ
03/08CELLTRION : Healthcare wins biosimilar deals in Singapore and Thailand
AQ
01/31CROWDREVIEWS PARTNERED WITH IMAPAC P : 8th Annual Biologics Manufacturing Korea ..
AQ
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
More sector news : Biotechnology & Medical Research - NEC
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 229 950,00  KRW
Last Close Price 184 500,00  KRW
Spread / Highest target 51,8%
Spread / Average Target 24,6%
Spread / Lowest Target -29,5%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Co-Chief Executive Officer & Director
Hyung-Ki Kim Co-Chief Executive Officer & Director
Myung-Geun Oh Vice President & Operations Manager
Jung-Jin Seo Director
Dong-Il Kim Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.20 071
IQVIA HOLDINGS INC34.16%30 740
LONZA GROUP31.57%25 623
INCYTE CORPORATION26.66%17 271
EXACT SCIENCES CORPORATION85.26%14 835
SEATTLE GENETICS, INC.32.49%12 140